Skin disorder caused by infection

Summary

Skin disorder caused by infection (MONDO:0024294) is a disease (an umbrella term covering 15 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include linezolid, omadacycline, and tigecycline. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 15 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin disorder caused by infection
Mondo ID	MONDO:0024294
MeSH	D012874
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	no

Also known as: disease, infectious skin · diseases, infectious skin · infectious skin disease · infectious skin diseases · skin disease, infectious

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › skin disorder caused by infection

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Subtypes (15): Epstein-Barr virus hepatitis, exanthema subitum, variola major infectious disease, common wart, plantar wart, herpetic whitlow, herpes zoster, chickenpox, hand, foot and mouth disease, viral exanthem, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, skin infection, skin disease caused by bacterial infection, parasitic skin disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Clotrimazole	Approved (phase 4)
Tigecycline	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00646958	PHASE2	COMPLETED	Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
NCT03716024	PHASE2	COMPLETED	Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
NCT00827541	Not specified	COMPLETED	Post-Authorization Study Evaluating Safety Of Tigecycline
NCT01789905	Not specified	COMPLETED	Tygacil Drug Use Investigation
NCT02991131	Not specified	TERMINATED	Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LINEZOLID	4	3
OMADACYCLINE	4	2
TIGECYCLINE	4	2
RADEZOLID	2	1
CHEMBL4468082	0	1